Niche focus Target large biotech players with muscular dystrophy pipelines and LAMA2 deficiency programs, offering rhLAM-111 as a complementary or adjunct therapeutic to enhance muscle repair strategies and potential combination therapies.

Small company agility Leverage Prothelia's lean team (11-50 employees) to position as a nimble partner for rapid collaboration on preclinical and early-stage trials, reducing operational friction and accelerating deal feasibility assessments.

Funding signals With current revenue under one million, emphasize funding roadmaps, grant opportunities, and milestone-based collaborations to de-risk early-stage engagements and align with potential partners seeking early access to novel assets.

Clinical alignment Identify partners with neuro-muscular and congenital muscular dystrophy portfolios; propose research collaborations, shared IP opportunities, or sponsored studies to validate rhLAM-111 efficacy in MDC1A models.

Digital readiness Utilize Prothelia’s tech stack and online presence to support co-marketing, investor materials, and virtual due diligence; offer ready-to-share clinical data packages and accelerated onboarding for alliance discussions.